Breaking News, Trials & Filings

FDA Approves MabPlex’s IND

MabPlex was contracted to develop and manufacture the product from cell line development to IND filing in both the United States and China

MabPlex International Ltd announced that an Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for its customer’s proprietary antibody drug.  MabPlex was contracted to develop and manufacture the product from cell line development to IND filing in both the United States and China. MabPlex provided fully integrated services from cell line development to final drug product including a complete CMC package in support of the United States I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters